Katie E. Archer

2.1k total citations
12 papers, 186 citations indexed

About

Katie E. Archer is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Katie E. Archer has authored 12 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Organic Chemistry and 6 papers in Molecular Biology. Recurrent topics in Katie E. Archer's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Synthesis and pharmacology of benzodiazepine derivatives (5 papers). Katie E. Archer is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Synthesis and pharmacology of benzodiazepine derivatives (5 papers). Katie E. Archer collaborates with scholars based in United States and United Kingdom. Katie E. Archer's co-authors include Ravi Chari, Erin K. Maloney, Michael L. Miller, Alan Wilhelm, Rajeeva Singh, Yelena Kovtun, Nathan Fishkin, Thomas A. Keating, Luke Harris and Wěi Li and has published in prestigious journals such as Cancer Research, British Journal of Pharmacology and Bioconjugate Chemistry.

In The Last Decade

Katie E. Archer

11 papers receiving 169 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katie E. Archer United States	6	114	97	89	43	10	12	186
Ludivine Moine United States	3	130 1.1×	119 1.2×	90 1.0×	24 0.6×	12 1.2×	3	198
Thayalan Navaratnam United States	2	131 1.1×	119 1.2×	68 0.8×	22 0.5×	12 1.2×	2	183
Simone Greven Germany	10	100 0.9×	113 1.2×	147 1.7×	52 1.2×	16 1.6×	17	230
Josefa dela Cruz-Chuh China	6	104 0.9×	99 1.0×	65 0.7×	39 0.9×	16 1.6×	6	150
Xiang Fang China	8	36 0.3×	18 0.2×	54 0.6×	16 0.4×	9 0.9×	30	131
Jeff Lau United States	2	100 0.9×	82 0.8×	38 0.4×	10 0.2×	3 0.3×	3	127
Johannes Toms Germany	5	133 1.2×	41 0.4×	37 0.4×	42 1.0×	4 0.4×	12	182
April Xu United States	8	67 0.6×	98 1.0×	90 1.0×	6 0.1×	13 1.3×	14	162
Wes Zmolek United States	4	151 1.3×	158 1.6×	128 1.4×	78 1.8×	11 1.1×	4	226
Miljen Martić Switzerland	7	50 0.4×	62 0.6×	65 0.7×	21 0.5×	7 0.7×	12	186

Countries citing papers authored by Katie E. Archer

Since Specialization

Citations

This map shows the geographic impact of Katie E. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katie E. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katie E. Archer more than expected).

Fields of papers citing papers by Katie E. Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katie E. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katie E. Archer. The network helps show where Katie E. Archer may publish in the future.

Co-authorship network of co-authors of Katie E. Archer

This figure shows the co-authorship network connecting the top 25 collaborators of Katie E. Archer. A scholar is included among the top collaborators of Katie E. Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katie E. Archer. Katie E. Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Bai, Chen, Alan Wilhelm, Erin K. Maloney, et al.. (2019). Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjugate Chemistry. 31(1). 93–103. 20 indexed citations

Archer, Katie E., James R. Woods, Luke Harris, et al.. (2019). Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1211–1215. 9 indexed citations

Archer, Katie E., Alan Wilhelm, Nicholas C. Yoder, et al.. (2019). Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1193–1197. 11 indexed citations

Archer, Katie E., Erin K. Maloney, Olga Ab, et al.. (2019). Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs). Bioorganic & Medicinal Chemistry Letters. 29(17). 2455–2458. 5 indexed citations

Archer, Katie E., Luke Harris, Erin K. Maloney, et al.. (2019). Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Molecular Pharmaceutics. 16(12). 4817–4825. 33 indexed citations

Miller, Michael L., Jose F. Ponte, Leanne Lanieri, et al.. (2017). Abstract 53: Antibody-drug conjugates (ADCs) of peptide-linked Indolino-Benzodiazepine (IGN) DNA-alkylator provides improved anti-tumor activity over that of a crosslinker. Cancer Research. 77(13_Supplement). 53–53. 1 indexed citations

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2016). A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics. 15(8). 1870–1878. 65 indexed citations

Vitharana, Dilrukshi, Alan Wilhelm, Luke Harris, et al.. (2016). Abstract 2965: In vitro and in vivo activity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent. Cancer Research. 76(14_Supplement). 2965–2965. 1 indexed citations

Whiteman, Kathleen R., Holly A. Johnson, Alan Wilhelm, et al.. (2013). Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.. Molecular Cancer Therapeutics. 12(11_Supplement). C162–C162.

10.

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2013). Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C160–C160. 1 indexed citations

11.

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2009). Abstract B126: Potent antigen-specific anti-tumor activity observed with antibody-drug conjugates (ADCs) made using a new class of DNA-crosslinking agents. Molecular Cancer Therapeutics. 8(12_Supplement). B126–B126. 5 indexed citations

12.

Cook, Susan, Katie E. Archer, A. Martin, et al.. (1995). Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. British Journal of Pharmacology. 114(1). 143–151. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact